PsychedelicNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while promoting focus, offsetting pain and inflammation and supporting circulation.”

To view the full article, visit http://cnw.fm/oUs26

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaEnergy.com.

More from PsychedelicNewsBreaks

• PsychedelicNewsBreaks – Psychedelic Therapeutics and Drug Development Conference Partners with PsychedelicNewsWire as Official Media Sponsor
• PsychedelicNewsBreaks – 4th Annual Psychedelic Therapeutics and Drug Development Conference to Bridge Gaps in Research and Development of Therapeutic Psychedelics
• PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com